In RET-rearranged tumors examples of these intracellular reactivated networks include RAS/MAPK signaling, which has been reported to confer resistance to MKI AD80 in RET-rearranged cell lines and to MKI ponatinib in preclinical patient-derived models of RET-fusion positive lung adenocarcinoma [100,102]. This evidence concerns the gene RET and lung adenocarcinoma.